Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-Reply

Daniel B Rubin¹, Caron Jacobson², Henrikas Vaitkevicius^{3

4}

Affiliations

¹ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Now with Clinical Development, Marinus Pharmaceuticals Inc, Radnor, Pennsylvania.

Comment

Daniel B Rubin et al. JAMA Neurol. 2021.

. 2021 Jun 1;78(6):764-765.

doi: 10.1001/jamaneurol.2021.0893.

Daniel B Rubin¹, Caron Jacobson², Henrikas Vaitkevicius^{3

4}

¹ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
³ Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Now with Clinical Development, Marinus Pharmaceuticals Inc, Radnor, Pennsylvania.

No abstract available

Comment on

Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, Spendley LN, Nikiforow S, Jacobson C, Vaitkevicius H. Rubin DB, et al. JAMA Neurol. 2020 Dec 1;77(12):1536-1542. doi: 10.1001/jamaneurol.2020.2703. JAMA Neurol. 2020. PMID: 32777012 Free PMC article.
Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Liu F, Tang X, Zhou L. Liu F, et al. JAMA Neurol. 2021 Jun 1;78(6):763-764. doi: 10.1001/jamaneurol.2021.0890. JAMA Neurol. 2021. PMID: 33900376 No abstract available.